Search for Companies, Tipsters or Sources…
Companies
Tipsters
Brokers
Sources
Or view the latest share tips
Company Results
Tipster results
Broker results
Sources results
Fund Manager results
Tips from these results
Recent Share tips:
- Buy Croda International (CRDA) by Stephen Wright in The Motley Fool
- Buy Aviva (AV.) by Ben McPoland in The Motley Fool
- Watch Auction Technology Group (ATG) by Oliver Rodzianko in The Motley Fool
- Buy Agronomics Limited (ANIC) by Sumayya Mansoor in The Motley Fool
- Buy Rolls-Royce Holdings (RR.) by Jefferies
- Avoid Pod Point Group Holdings (PODP) by Steve Moore in ShareProphets
- Buy Tharisa (DI) (THS) by Hot Stock Rockets in ShareProphets
- Avoid Cyanconnode Holdings (CYAN) by Steve Moore in ShareProphets
- Buy Legal & General Group (LGEN) by Christopher Ruane in The Motley Fool
- Avoid Zenova Group (ZED) by Steve Moore in ShareProphets
- Hold Team17 Group (TM17) by Jefferies
- Hold BP (BP.) by Mark David Hartley in The Motley Fool
- Buy Intertek Group (ITRK) by Redburn Partners
- Buy IQE (IQE) by Numis
- Hold 888 Holdings (DI) (888) by Numis
- Buy Oxford Metrics (OMG) by Numis
- Buy Hunting (HTG) by Kepler Cheuvreux
- Add Man Group (EMG) by Numis
- Buy NATWEST GROUP (NWG) by Peel Hunt
- Overweight VinaCapital Vietnam Opportunity Fund Ltd. (VOF) by Barclays
Shield Therapeutics (STX) Share Price
Health Care Sector
NOTE: This is based on 59 open tips for Shield Therapeutics (STX)
| Latest Bid : 1.45p | Latest Ask : 1.50p |
| High Today : 1.50p | Low Today : 1.42p |
| This Years High : 12.50p | This Years Low : 1.42p |
| Volume : 1,069,489 | MKT Cap : £11.73M |
| Trading Velocity : Premium Only | Activity Score : Premium Only |
| Consensus Score : Premium Only | Momentum Score : Premium Only |
Shield Therapeutics (STX) Overview
Shield is a de-risked commercial stage, pharmaceutical company focused on addressing iron deficiency in adults with or without anaemia. Our clear purpose is to develop products that help patients become people again, enabling them to enjoy the things that make a difference in their everyday lives.Shield Therapeutics (STX) Latest Tips
| Type | Tipster | SectorScore | Start date | Performance |
|---|---|---|---|---|
| Sell | Tom Winnifrith | Premium Only | 2024-02-21 12:20:00 21/02/2024 | 48.28% |
| Buy | William Kay | Premium Only | 2023-09-29 00:05:00 29/09/2023 | -81.05% |
| Buy | Peel Hunt | Premium Only | 2023-02-09 09:31:00 09/02/2023 | -79.58% |
| Sell | Tom Winnifrith | Premium Only | 2022-06-30 08:40:00 30/06/2022 | 81.25% |
| Sell | Tom Winnifrith | Premium Only | 2022-06-12 17:55:00 12/06/2022 | 89.55% |
Shield Therapeutics (STX) Active Short Positions
| Fund Manager | Position | Date | ||
|---|---|---|---|---|
| No active short positions | ||||
| Latest Bid : 1.45p | Latest Ask : 1.50p |
| High Today : 1.50p | Low Today : 1.42p |
| This Years High : 12.50p | This Years Low : 1.42p |
| Volume : 1,069,489 | MKT Cap : £11.73M |
Shield Therapeutics Overview
Shield is a de-risked commercial stage, pharmaceutical company focused on addressing iron deficiency in adults with or without anaemia. Our clear purpose is to develop products that help patients become people again, enabling them to enjoy the things that make a difference in their everyday lives.NOTE: This description is in part generated by ChatGPT and not an endorsement by or the opinion of Stockomendation Ltd.
Latest Shield Therapeutics Tips
| Type | Tipster | SectorScore | Start date | Performance |
|---|---|---|---|---|
| Sell | Tom Winnifrith | Premium Only | 2024-02-21 12:20:00 21/02/2024 | 48.28% |
| Buy | William Kay | Premium Only | 2023-09-29 00:05:00 29/09/2023 | -81.05% |
| Buy | Peel Hunt | Premium Only | 2023-02-09 09:31:00 09/02/2023 | -79.58% |
| Sell | Tom Winnifrith | Premium Only | 2022-06-30 08:40:00 30/06/2022 | 81.25% |
| Sell | Tom Winnifrith | Premium Only | 2022-06-12 17:55:00 12/06/2022 | 89.55% |